Targeting ubiquitin-specific peptidase 22 to control tumor growth

 5
Targeting ubiquitin-specific peptidase 22 to control tumor growth

As a ‘death-from-cancer’ signature gene, ubiquitin-specific protease 22 is broadly upregulated across human cancers, predicts poor clinical outcomes, and is associated with therapeutic resistance. 

Ubiquitin-specific protease 22 amplifies context-dependent, tumor-intrinsic oncogenic programs that promote cancer cell growth, survival, metabolic reprogramming, stemness, migration, and metastasis.

Ubiquitin-specific protease 22 drives immune evasion by promoting regulatory T cell adaptation, inducing M2 macrophage polarization, upregulating immune checkpoint pathways, and suppressing neoantigen presentation.

Targeting ubiquitin-specific protease 22 offers dual benefits by blocking oncogenic signaling and enhancing antitumor immunity, supporting ubiquitin specific protease 22 as a first-in-class therapeutic target.
#sciencenewshighlights #ScienceMission
https://www.cell.com/trends/molecular-medicine/fulltext/S1471-4914(26)00163-2
https://sciencemission.com/Ubiquitin-specific-peptidase-22